Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II VEPEMB study in patients over 60 years with Hodgkin's lymphoma
ISRCTN87375595Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Sep 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide and 2 more in Hodgkin lymphoma (HL) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Progression-free survival and Overall survival. Started Sep 2004; status: completed.
02
Drugs
vinblastinecyclophosphamideprocarbazineprednisoloneetoposide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ISRCTN87375595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87375595.